AHO is a commercial-stage specialty pharma pioneering in oral, transdermal drug delivery systems. Collaborating with our partners across three continents, our pipeline of medicines targets CNS, Geriatric, and Pediatric therapies that provide caregivers with significant treatment options. From concept to commercial, we have several products launched in major markets. Trusted by partner pharma, we devote toward partner value and innovation. | TAHO Pharmaceuticals, founded in 2010 in Taipei, Taiwan, and listed on the Taipei Exchange, is dedicated to transforming drug delivery with heart and innovation. We specialize in advanced formulations that make oral and injectable medications safer, more effective, and easier to use. Our mission is to enhance patient lives with thoughtful, next-generation solutions for diverse needs, especially those struggling with traditional treatments. Our success stems from our proprietary Transepithelial Delivery System (TDS) platform. It features: Transdermal Delivery: Patches provide steady medication through the skin, eliminating injections or frequent dosing—ideal for chronic care. Transmucosal Delivery: Oral thin films ensure rapid onset, enhanced bioavailability, and improved experience via the mucosa. We’re not merely creating new delivery methods—we are redefining the future of healthcare with compassion, ensuring our innovations bring hope and comfort to patients and caregivers. | TAHO Pharmaceuticals Ltd., founded in 2010 and headquartered in Taipei, Taiwan, is a publicly listed company on the Taipei Exchange. The company focuses on advancing drug delivery through innovative formulation technologies that improve the safety, efficacy, and convenience of existing medications. Leveraging its proprietary Transepithelial Delivery System (TDS) platform, TAHO develops transdermal and transmucosal drug delivery solutions designed to enable efficient drug absorption, improve patient compliance, and optimize therapeutic outcomes. By creating patient-friendly alternatives to traditional oral and injectable medications, TAHO is committed to addressing unmet medical needs and improving quality of life for patients worldwide. | TAHO is an R&D-driven specialty pharma pioneering oral and transdermal drug-delivery systems. TAHO’s Transepithelial Delivery System enables the development of oral dissolving films and transdermal patches for anticoagulants and many other treatments
Tai Hong Circuit Industrial Co., Ltd.
Established in 1969, TCI is the oldest professional printed circuit board manufacturing company in Taiwan. It has been deeply cultivating Taiwan and fulfilling its social responsibilities. As a part of the automotive supply chain, with the rapid development of electric vehicles around the world, we continue to upgrade process equipment and increase production capacity, thereby enhancing Taiwan’s industrial competitiveness.
T-E Meds Inc.
T-E Meds is a biotechnology company that specializes in the discovery and development of novel therapies for the treatment of cancer and other diseases. Our proprietary technology platforms are based on innovative “Multi-Arm Linkers” and proprietary bioconjugation methods, and can be applied in antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs). The company was founded by Dr. Tse Wen Chang, a renowned expert in entrepreneurship and new drug development, who co-founded Tanox, Inc., founded Immunwork, Inc., and invented anti-IgE therapy (Xolair). T-E Meds’ ADC/ARC technology platforms use an enzyme-free click reaction to generate site-specific conjugation ADC/ARCs with a high drug-to-antibody ratio (DAR), high reaction yield, and high purity. The dual-payload design is feasible to conjugate two different payloads to one single antibody molecule with one conjugation step. The “Drug Bundle,” a unique payload/linker design based on Multi-Arm Linkers, allows multiple copies of payload molecules to be conjugated to the antibody at one conjugation site. The payload selection, payload number, cleavability of the linker, hydrophilicity of the Drug Bundle, and conjugation group/method are subjects to be selected for appropriated ADC designs. T-E Meds’ innovative ADC / ARC technology platform can be considered best-in-class. T-E Meds has a robust pipeline of drug candidates in various stages of discovery and preclinical development. Our lead product candidate, TE-1146, is an ADC designed to selectively target multiple myeloma cells and spare healthy tissue. In several animal models, TE-1146 demonstrated superior treatment efficacy compared to daratumumab/lenalidomide combo regimen. Currently, TE-1146 is in preclinical CMC development. Another promising product candidate, TE-1132, an ARC designed to selectively target pancreatic cancer cells, is in preclinical development. TE-1132 can be applied in SPECT/CT image diagnosis and radiotherapy. In several animal models, TE-1132 displayed strong potential in both diagnosis and therapy. T-E Meds is actively raising funds to support the continuous development of our technology platforms and pipeline products. The company was recently spun-off from Immunwork, Inc. in November 2022 and is currently raising the first round of financing. We are open to discussing various types of collaborations, including platform licensing, drug product licensing, co-development, or other R&D collaborations. Dr. Tse Wen Chang’s extensive experience in entrepreneurship and new drug development has enabled T-E Meds to establish a strong foundation for innovative technology platforms and a de-risked pipeline. This, along with the company’s best-in-class platforms, demonstrates our commitment to advancing the field of cancer therapy, as well as ADC / ARC drug discovery and development.
Syntec Scientific Corporation
Syntec Scientific Corporation was found in 1995 by a group of Doctors and Engineers to develop and to manufacture surgical skeleton products. Syntec Scientific Corporation now is the leading company in Taiwan specialize in skeleton products and medical instruments in the Orthopedic Industry. Syntec Scientific Corporation will always achieve this position by professional pursuing excellence and by dedicating ourselves in improving the quality and serving all our customers.
SyncVision Technology Corporation
SyncVision Technology Corp. is a medtech innovator delivering complete digital diagnostic solutions—beyond imaging. We develop, manufacture, and commercialize a full product portfolio including digital ENT scopes, electronic stethoscopes, and integrated vital sign devices, designed for clinical workflows, telemedicine, and point-of-care use. With deep expertise in optical design, embedded systems, and medical-grade product engineering, we help healthcare partners accelerate development from concept to mass production. Our solutions are supported by software integration capabilities (SDK/DLL) for seamless connectivity with third-party platforms and hospital systems. SyncVision products and systems have achieved key regulatory clearances and certifications, including FDA, CE, and Japan PMDA, enabling global deployment with OEM/ODM customers and channel partners.
Superlux
Superlux, founded on the belief in “Creating the Value of Sound”, passionately delivers exceptional audio quality worldwide. For 38 years, our innovative R&D team has refined electroacoustic technology, bringing groundbreaking products to over 100 countries and making premium sound accessible to all.
Superlee
Superlee is a manufacturer dedicated in providing innovative vehicle lighting solutions. Besides a full range of off-the-shelf lights available for customer selection, we also take on OEM/ODM projects that are custom-designed to meet each customer’s unique application.